PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, ...
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee ...
Patients with sickle cell disease and beta-thalassemia treated with exagamglogene autotemcel reported substantial and ...
Agios Pharmaceuticals said a key European regulatory committee has recommended expanded approval of its Pyrukynd anemia drug for certain people with the inherited blood disorder thalassemia. Agios on ...
With the bull market starting its fourth year, and yields on U.S. debt falling to the lowest levels since early this year, ...
Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year -- Second pivotal development ...
For two decades, US biotech Vertex (Nasdaq: VRTX) built a reputation as one of the few companies to pair cutting-edge science ...
During a meeting this week, an expert panel of the EU drug regulator, the European Medicines Agency (EMA), has endorsed two ...
India faces a silent anaemia epidemic, with rising cases across all demographics. In most cases, public tend to disregard its ...
Zacks Investment Research on MSN
BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
Shares of Bristol Myers BMY continue to lose momentum in 2025. In fact, the stock lost 4.7% in a month against the industry’s ...
7don MSN
Nearly 90% of adults are at risk for this condition, but most have never heard of it, survey finds
About 9 in 10 adults in the United States have not heard of cardiovascular-kidney-metabolic syndrome despite nearly 90% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback